|
Name |
trans-13-Octadecenoic acid
|
| Molecular Formula | C18H34O2 | |
| IUPAC Name* |
(E)-octadec-13-enoic acid
|
|
| SMILES |
CCCC/C=C/CCCCCCCCCCCC(=O)O
|
|
| InChI |
InChI=1S/C18H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h5-6H,2-4,7-17H2,1H3,(H,19,20)/b6-5+
|
|
| InChIKey |
BDLLSHRIFPDGQB-AATRIKPKSA-N
|
|
| Synonyms |
trans-13-Octadecenoic acid; 13-Octadecenoic acid; 693-71-0; TRANS-13-OCTADECENOICACID; (E)-octadec-13-enoic acid; 13E-octadecenoic acid; (E)-13-Octadecenoic acid; 7378-89-4; 18:1(13E); C18:1n-5; (Z)-octadec-13-enoic acid; (13E)-octadec-13-enoic acid; (13E)-octadecenoic acid; 13-Octadecenoic acid, (Z)-; SCHEMBL2320463; DTXSID60880901; CHEBI:143770; ZINC5260607; LMFA01030880
|
|
| CAS | 693-71-0 | |
| PubChem CID | 6161490 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 282.5 | ALogp: | 7.2 |
| HBD: | 1 | HBA: | 2 |
| Rotatable Bonds: | 15 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 37.3 | Aromatic Rings: | 0 |
| Heavy Atoms: | 20 | QED Weighted: | 0.289 |
| Caco-2 Permeability: | -5.097 | MDCK Permeability: | 0.00002960 |
| Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.755 |
| 30% Bioavailability (F30%): | 0.959 |
| Blood-Brain-Barrier Penetration (BBB): | 0.02 | Plasma Protein Binding (PPB): | 99.94% |
| Volume Distribution (VD): | 0.856 | Fu: | 0.59% |
| CYP1A2-inhibitor: | 0.284 | CYP1A2-substrate: | 0.189 |
| CYP2C19-inhibitor: | 0.203 | CYP2C19-substrate: | 0.066 |
| CYP2C9-inhibitor: | 0.215 | CYP2C9-substrate: | 0.993 |
| CYP2D6-inhibitor: | 0.023 | CYP2D6-substrate: | 0.101 |
| CYP3A4-inhibitor: | 0.05 | CYP3A4-substrate: | 0.017 |
| Clearance (CL): | 2.403 | Half-life (T1/2): | 0.768 |
| hERG Blockers: | 0.048 | Human Hepatotoxicity (H-HT): | 0.035 |
| Drug-inuced Liver Injury (DILI): | 0.018 | AMES Toxicity: | 0.002 |
| Rat Oral Acute Toxicity: | 0.015 | Maximum Recommended Daily Dose: | 0.021 |
| Skin Sensitization: | 0.932 | Carcinogencity: | 0.043 |
| Eye Corrosion: | 0.964 | Eye Irritation: | 0.959 |
| Respiratory Toxicity: | 0.832 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001100 | ![]() |
0.932 | D0O1PH | ![]() |
0.809 | ||
| ENC001592 | ![]() |
0.932 | D0O1TC | ![]() |
0.600 | ||
| ENC001555 | ![]() |
0.932 | D07ILQ | ![]() |
0.539 | ||
| ENC001591 | ![]() |
0.932 | D0UE9X | ![]() |
0.520 | ||
| ENC001419 | ![]() |
0.932 | D0Z5BC | ![]() |
0.500 | ||
| ENC001593 | ![]() |
0.875 | D0Z5SM | ![]() |
0.461 | ||
| ENC001099 | ![]() |
0.831 | D05ATI | ![]() |
0.444 | ||
| ENC001589 | ![]() |
0.831 | D0OR6A | ![]() |
0.438 | ||
| ENC001553 | ![]() |
0.800 | D09SRR | ![]() |
0.435 | ||
| ENC001687 | ![]() |
0.800 | D0XN8C | ![]() |
0.432 | ||